Dr. Matthew Hahn on the Importance of Destigmatizing OUD Treatment

FDA’s Rare Disease Day 2026 – An Event for Patients

Dr. Matthew Hahn on Treating OUD with Medication

Roundtable on PMTA Submissions for ENDS Products

FDA Direct: Combating Rare Diseases at the FDA

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

Dr. Mina Tanaka on Stigma and Requirements for Prescribing MOUD

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Expert Panel on Food Allergies

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA Celebrates 120 Years

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products